National estimates of antidepressant medication use among U.S. Children, 1997-2002

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 45, Issue 3, 2006, Pages 271-279

  Vitiello, Benedetto ^a   Zuvekas, Samuel H ^b   Norquist, Grayson S ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Antidepressants; Children; Pharmacoepidemiology; Use

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CHILD; CHILD PSYCHIATRY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG USE; EUROPEAN AMERICAN; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SURVEY; HISPANIC; HOUSEHOLD; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NEWBORN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DEPRESSION; DRUG UTILIZATION; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; PREVALENCE; UNITED STATES;

EID: 33645105194     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000192249.61271.81     Document Type: Article

References (33)

1. American Academy of Child and Adolescent Psychiatry (2004), Practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry 43:1540-1550
2. Bird H, Andrews H, Schwab-Stone M et al. (1996), Global measures of impairment for epidemiologic and clinical use with children and adolescents. J Methods Psychiatr Res 6:295-307
3. Birmaher B, Brent DA, Benson RS (1998), Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 37:1234-1238
4. Costello EJ, Mistillo S, Erkanli A, Keeler G, Angold A (2003), Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 60:837-844
5. Delate T, Gelenberg AJ, Simmons VA, Motheral BR (2004), Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv 55:387-391
6. Emslie GJ, Heligenstein JH, Wagner KD et al. (2002), Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215
7. Emslie GJ, Rush AJ, Weiberg WA et al. (1997), A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037
8. Flament MF, Whitaker A, Rapoport JL et al. (1988), Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27:764-771
9. Hammad TA (2004), Results of the analysis of suicidality in pediatric trials of newer antidepressants. Presented at the U.S. Food and Drug Administration, Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee, September 13, 2004; http://www.fda.gov/ohrms/dockets/ac/04/ slides/2004-4065s1_08_fda-hammad_files/frame. htm, accessed September 29, 2005
10. Hughes CW, Emslie GJ, Crismon ML et al. (1999), The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 38:1442-1454
11. Hunkeler EM, Fireman B, Lee J et al. (2005), Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003. J Child Adolesc Psychopharmacol 15:26-37
12. Kessler RC, Avenevoli S, Merikangas KR (2001), Mood disorders in children and adolescents: an epidemiologic perspective. Biol Psychiatry 49:1002-1014
13. Kessler RC, Walters EE (1998), Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 7:3-14
14. Lewinsohn PM, Rohde P, Seeley JR (1998), Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev 18:765-794
15. March JS, Biederman J, Wolkow R et al. (1998), Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280:1752-1756
16. Mitka M (2003), FDA alert on antidepressants for youth. JAMA 290:2534
17. Moeller JF, Stagnitti MN, Horan E (2001), Outpatient prescription drugs: data collection and editing in the 1996 Medical Expenditure Survey (HC-010A) (Pub. No. 01-0002). Rockville, MD: Agency for Healthcare Research and Quality
18. National Center for Health Statistics (2004), Health, United States, 2004. With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics
19. Olfson M, Gameroff MJ, Marcus SC, Waslick BD (2003a), Outpatient treatment of child and adolescent depression in the United States. Arch Gen Psychiatry 60:1236-1242
20. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA (2002b), National trends in the outpatient treatment of depression. JAMA 287:203-209
21. Olfson M, Marcus SC, Weissman MM, Jensen PS (2002a), National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514-521
22. Olfson M, Shaffer D, Marcus SC, Greenberg T (2003b), Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60:978-982
23. Pliszka SR, Greenhill LL, Crimson ML et al. (2000), The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 39:908-919
24. Rosack J (2005), New data show declines in antidepressant prescribing. Psychiatr News 40:1
25. RUPP Anxiety Study Group (2001), RUPP Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285
26. Simonoff E, Pickles A, Meyer JM, Silberg JL, Maes HH, Loeber R, Rutter M, Hewitt JK, Eaves LJ (1997), The Virginia Twin Study of Adolescent Behavioral Development. Influences of age, sex, and impairment on rates of disorder. Arch Gen Psychiatry 54:801-808
27. Spencer T, Biederman J, Wilens T (2004), Nonstimulant treatment of adult attention-dencit/hyperactivity disorder. Psychiatr Clin North Am 27:373-383
28. Selden TM, Levit KR, Cohen JW et al. (2002), Reconciling medical expenditure estimates from the MEPS and the NHA, 1996. Am J Public Health 92:231-234
29. U.S. Food and Drug Administration (2004), FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. FDA News, October 15, 2004; http://www.fda.gov/bbs/topics/news/ 2004/new01124.html, accessed June 1, 2005
30. U.S. Food and Drug Administration (2005), Class suicidality labeling language for antidepressants, February 3, 2005; http://www.fda.gov/cder/drug/ antidepressants/pi_template.pdf, accessed June 1, 2005
31. Valleni-Basile LA, Garrison CZ, Jackson KL et al. (1994), Frequency of obsessive-compulsive disorder in a community sample of young adolescents. J Am Acad Child Adolesc Psychiatry 34:128-129
32. Zito JM, Safer DJ, dosReis S et al. (2002), Rising prevalence of antidepressants among US youth. Pediatrics 109:721-727
33. Zuvekas SH (2005), Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Affairs 24:195-205